Insmed Incorporated (NASDAQ:INSM) announced additional positive results from its Phase 3 ASPEN study on July 3, 2024.

The study evaluated brensocatib's efficacy, safety, and tolerability in patients with non-cystic fibrosis bronchiectasis.

The study showed a significant reduction in pulmonary exacerbations and improved lung function, positioning brensocatib as a potential first approved treatment for bronchiectasis.

Lead investigator James Chalmers emphasized the urgency for new treatments, stating, "The ASPEN findings are critically important given that there is no approved treatment for bronchiectasis."